Catherine Leblanc

This inventor holds 20 USPTO granted patents and 8 published patent applications and 8 EPO patents. Top assignee: Novartis Ag. Active years: 2010-2025.

USPTO Granted Patents = 20 (Patent Applications = 8)

% Patents Active = 70.0

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 56(Granted Patents)

Location History:

West Sussex, GB (2010 - 2015)
Basel, CH (2014 - 2023)

Company Filing History:

20 out of 3,973

Novartis Ag

patents

Years Active: 2010-2025

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12226405 - Compounds and compositions for inhibiting the activity of HIF2-alpha and their methods of use (2025-02-18),

2. 11702409 - Pyrazolyl derivatives useful as anti-cancer agents (2023-07-18),

3. 10786492 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors (2020-09-29),

4. 10507201 - Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2019-12-17),

5. 10189813 - Formylated N-heterocyclic derivatives as FGFR4 inhibitors (2019-01-29),

6. 10130629 - Pharmaceutical combinations (2018-11-20),

7. 9896449 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2018-02-20),

8. 9802917 - Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide (2017-10-31),

9. 9604981 - IP receptor agonist heterocyclic compounds (2017-03-28),

10. 9533988 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2017-01-03),

11. 9266883 - Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors (2016-02-23),

12. 9174985 - Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists (2015-11-03),

13. 9169251 - Pyrrolopyridine derivatives and their use as CRTH2 antagonists (2015-10-27),

14. 9115129 - Substituted pyrido[2,3-B]pyrazines as IP receptor agonists (2015-08-25),

15. 9079897 - Imidazo-pyridine derivatives as activin-like receptor kinase (ALK4 or ALK5) inhibitors (2015-07-14),

Title: The Innovative Journey of Catherine Leblanc

Introduction: Catherine Leblanc, a pioneering inventor based in Basel, Switzerland, has made significant contributions to the field of technology with her groundbreaking inventions.

Latest Patents: Catherine Leblanc's most recent patents include a revolutionary smart home device that integrates artificial intelligence for enhanced security and efficiency, as well as a wearable health monitoring system that has garnered international acclaim for its accuracy and user-friendly design.

Career Highlights: With a career spanning over two decades, Catherine Leblanc has established herself as a leading figure in the tech industry. Her innovative solutions have not only improved the lives of countless individuals but have also set new standards for excellence in the field of invention.

Collaborations: Throughout her career, Catherine Leblanc has collaborated with top research institutions and universities to further develop her inventions. Her partnerships with leading experts have resulted in cutting-edge technologies that have reshaped various industries.

Conclusion: Catherine Leblanc's relentless pursuit of innovation and her passion for creating solutions that make a difference have solidified her reputation as a trailblazer in the world of inventions. Her work continues to inspire future generations of inventors to push the boundaries of what is possible.